Given the side effect issues associated with PPARγ agonists, including tumor formation, bone fractures, weight gain, and fluid retention53, targeting NLRC5 may provide a valuable means to modulate PPARγ signaling and potentially overcome these issues. The gene discussed is PPARG; the disease is neoplasm.